Obiettivo The opportunity to focus on the production of biopharmaceuticals is often taken from SMEs since huge amount of resources is required for the development of high-producer cell lines. We envision that our parental cell factories will increase the efficiency of cell line engineering and will effectively reduce the time-to-market for mammalian cell-based products. It allows SMEs to leverage their traditional strengths of adaptability and creativity, and to develop novel products for biotechnology industries. Campo scientifico natural sciencesbiological sciencesbiochemistrybiomoleculesproteins Programma(i) H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Argomento(i) BIOTEC-5a-2014-1 - SME boosting biotechnology-based industrial processes driving competitiveness and sustainability Invito a presentare proposte H2020-SMEInst-2014-2015 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-1-2014 Meccanismo di finanziamento SME-1 - SME instrument phase 1 Coordinatore ICOSAGEN CELL FACTORY OU Contribution nette de l'UE € 50 000,00 Indirizzo EERIKA TEE 1 61713 Kambja Vald Estonia Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Eesti Eesti Lõuna-Eesti Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 71 429,00
